Xilio Therapeutics (formerly Akrevia Therapeutics) is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics. It applies its proprietary technology that enables to increase therapeutic activity specifically within the tumor while reducing toxicity throughout the body. The company builds a broad pipeline of engineered antibodies, cytokines, and chemokines.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Apr 2021)||57||(+8%)|
Xilio Therapeutics total Funding
Xilio Therapeutics latest funding size
Time since last funding
|3 years ago|
Xilio Therapeutics investors
|Atlas Venture, F-Prime Capital Partners|
Xilio Therapeutics has 90 Twitter Followers. The number of followers has increased 46.3% month over month and increased 101.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Xilio Therapeutics founded?
Xilio Therapeutics was founded in 2015.
Who are Xilio Therapeutics key executives?
Xilio Therapeutics's key executives are Joe Farmer, Rene Russo and Tim Clackson.
How many employees does Xilio Therapeutics have?
Xilio Therapeutics has 57 employees.
Who are Xilio Therapeutics competitors?
Competitors of Xilio Therapeutics include Kiromic Biopharma, OncoArendi Therapeutics and Luye Pharma.
Where is Xilio Therapeutics headquarters?
Xilio Therapeutics headquarters is located at 610 Main St, Cambridge.
Where are Xilio Therapeutics offices?
Xilio Therapeutics has an office in Cambridge.
How many offices does Xilio Therapeutics have?
Xilio Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies